Down Syndrome: The Role of Genomic Medicine in Prenatal Screening

Introduction

Down syndrome, also known as Trisomy 21, is one of the most prevalent chromosomal abnormalities affecting children worldwide. It arises from the presence of an extra copy of chromosome 21, leading to a variety of clinical characteristics such as distinctive facial features, developmental delay, and an increased risk of congenital heart and metabolic disorders.

Globally, Down syndrome is estimated to occur in approximately one in every 700 live births, though its prevalence differs across regions due to variations in maternal age distribution, healthcare access, and prenatal screening practices. In Europe, significant advances in genomic diagnostics and reproductive medicine have influenced detection rates, allowing families to make more informed decisions and improving the overall understanding of the condition.

Within paediatrics, Down syndrome represents not only a clinical challenge but also an opportunity to apply the principles of preventive genomic medicine. As genomic technologies become increasingly integrated into early pregnancy care, the potential to identify chromosomal abnormalities before or during gestation has greatly expanded.

Genomic medicine, which utilises genome-wide data to guide clinical decision-making, now plays a pivotal role in the prevention and early detection of Down syndrome. Techniques such as non-invasive prenatal testing (NIPT), chorionic villus sampling, and amniocentesis allow accurate identification of chromosomal anomalies, while preimplantation genetic testing (PGT) offers the possibility of preventing affected pregnancies through assisted reproductive technologies.

The aim of this paper is to examine how genomic medicine contributes to the prevention of Down syndrome, focusing on its role in early screening, genetic counselling, and the ethical dimensions of reproductive decision-making in paediatric care.

Genetic Basis of Down Syndrome

Down syndrome is primarily caused by an alteration in the number of chromosomes, resulting in the presence of an extra copy of chromosome 21. This additional genetic material disrupts normal patterns of gene expression and development, producing the characteristic physical and cognitive features associated with the condition.

There are three main chromosomal forms of Down syndrome:

1. Full (Free) Trisomy 21 – This is the most common type, accounting for approximately 95 % of cases. In this form, every cell in the body contains three copies of chromosome 21 instead of the usual two.

2. Mosaic Trisomy 21 – Representing around 2–3 % of cases, this type occurs when only a proportion of the body’s cells carry the extra chromosome 21. The degree of mosaicism often influences the severity of clinical features.

3. Translocation Trisomy 21 – Found in about 3–4 % of cases, this form arises when part or all of chromosome 21 is attached to another chromosome, typically chromosome 14 or 22. Unlike the other types, this variant may be inherited, making parental chromosomal analysis essential for assessing recurrence risk and guiding preventive genetic counselling.

The underlying mechanism responsible for Trisomy 21 is known as nondisjunction, an error that occurs during the formation of reproductive cells (meiosis). When the two copies of chromosome 21 fail to separate properly, one gamete receives an extra chromosome. Following fertilisation, the resulting embryo has three copies of chromosome 21 in each cell. The likelihood of nondisjunction increases with maternal age, making maternal age one of the most significant risk factors for Down syndrome.

The presence of this additional chromosome leads to a gene dosage imbalance, meaning that genes on chromosome 21 are overexpressed. This overexpression disrupts multiple cellular and developmental pathways, influencing brain development, heart formation, and immune regulation. Specific genes—such as DYRK1A, APP, and SOD1—have been linked to the neurological, cognitive, and metabolic features commonly seen in affected individuals.

In simple terms, the “extra genome” in Down syndrome results in an overload of certain gene products, which interferes with normal cellular balance and development. Understanding these genomic mechanisms not only provides insight into the condition’s clinical manifestations but also forms the foundation for preventive genomic strategies aimed at early detection and informed reproductive decision-making.

Clinical Manifestations and Genomic Correlations

Down syndrome presents with a broad spectrum of physical, cognitive, and developmental features. Common physical characteristics include a flat facial profile, upward slanting eyes, single palmar crease, and hypotonia. Cognitive and developmental manifestations vary widely, ranging from mild to moderate intellectual disability, delayed speech and motor milestones, and learning difficulties. Additional medical complications may include congenital heart defects, gastrointestinal anomalies, endocrine disorders, and increased susceptibility to infections.

Advances in genomic research have enabled the identification of specific genes on chromosome 21 that contribute to these phenotypic traits. For example:

• DYRK1A is implicated in neurodevelopmental delay and cognitive impairment.

• APP (Amyloid Precursor Protein) is associated with early-onset Alzheimer-like pathology observed in many adults with Down syndrome.

• SOD1 (Superoxide Dismutase 1) contributes to oxidative stress, which may affect multiple organ systems.

By correlating genomic variation with clinical presentation, researchers can identify the molecular pathways underlying the condition. Such studies provide critical insights into the mechanisms driving both common and variable features of Down syndrome, offering potential targets for preventive interventions, personalised care, and early therapeutic strategies.

Through these genomic correlations, clinicians and researchers are better equipped to predict individual outcomes, tailor monitoring plans, and support families with accurate, evidence-based guidance.

Genomic Medicine in the Management and Therapy of Down Syndrome

Current Therapies and Multidisciplinary Care for Children with Down Syndrome

Management of Down syndrome currently relies on comprehensive, multidisciplinary care. Paediatricians, cardiologists, endocrinologists, speech and occupational therapists, and educational specialists collaborate to address the physical, cognitive, and developmental needs of affected children. Early intervention programmes, regular health monitoring, and supportive therapies remain the cornerstone of improving quality of life.

Emerging Research: Gene Therapy and Targeted Genomic Approaches in Down Syndrome

Recent advances in genomic medicine have opened new avenues for potential therapies in Down syndrome. Research is exploring gene-targeted interventions and strategies to modulate gene expression, aiming to correct or mitigate the effects of trisomy 21 at a molecular level. Although clinical application remains in early stages, these studies demonstrate the promise of precision genomic interventions for improving neurological and systemic outcomes.

Induced Pluripotent Stem Cells (iPSCs) as Models for Down Syndrome Research

iPSCs derived from individuals with Down syndrome provide powerful models to study the cellular and molecular consequences of an extra chromosome 21. These models enable researchers to investigate gene expression patterns, identify therapeutic targets, and test novel interventions in vitro, accelerating the translation of genomic discoveries into potential treatments.

Precision Medicine Approaches for Enhancing Quality of Life in Down Syndrome

By integrating genomic data into personalised care plans, clinicians can tailor interventions to the individual child’s genetic profile. Precision medicine in Down syndrome supports:

• Early identification of risk factors for congenital heart disease or metabolic disorders

• Optimised educational and developmental strategies

• Personalised pharmacological approaches based on genomic insights

Through these genomic-informed strategies, management of Down syndrome is increasingly preventive, personalised, and proactive, offering better long-term outcomes and improved quality of life for children and families.

Ethical, Legal and Social Implications of Genomic Prevention in Down Syndrome

Prenatal and paediatric genomic approaches in Down syndrome raise important ethical, legal, and social considerations. Addressing these ensures responsible use of genomic medicine while supporting families in making informed choices.

Hover over each box for more detailed information!

Ethical Considerations in Prenatal Screening

Families face complex decisions when trisomy 21 is detected.

Clinicians must provide non-directive, evidence-based counselling respecting parental autonomy, addressing potential psychological impact, and clearly communicating medical outcomes and implications.

Family Rights & Data Privacy

Genomic medicine generates extensive personal and familial data requiring protection.

Families must be informed about storage, sharing, and use of genomic information, including implications for insurance, employment, and future reproductive choices, with robust consent and privacy safeguards in place.

Social and Cultural Challenges

Societal attitudes and cultural norms shape perceptions of Down syndrome.

Stigma, misinformation, and cultural values can affect decision-making and screening uptake. Addressing these challenges requires culturally sensitive education, public engagement, and policies supporting informed choice without coercion.

Responsible genomic prevention. Considering ethical, legal, and social dimensions ensures that prenatal and paediatric genomic approaches in Down syndrome support families, protect rights, and foster informed and respectful decision-making.

Future Directions and Research Opportunities in Genomic Medicine for Down Syndrome

Development of More Accurate Genomic Tests

Future research in genomic medicine aims to refine and expand prenatal and postnatal testing for Down syndrome. Innovations in sequencing technologies, improved bioinformatics pipelines, and non-invasive approaches promise higher sensitivity and specificity, enabling earlier detection and more informed reproductive decision-making.

Gene-Based Therapeutic Approaches

Emerging studies are exploring gene-targeted therapies to modulate the effects of the extra chromosome 21. Techniques such as gene silencing, RNA interference, and CRISPR-based strategies may offer opportunities to correct or mitigate specific molecular pathways, potentially reducing the severity of clinical manifestations and improving long-term outcomes.

Integration of Bioinformatics and Artificial Intelligence

The combination of bioinformatics and artificial intelligence (AI) provides powerful tools for predicting phenotypic outcomes, understanding gene–gene interactions, and identifying at-risk individuals. Machine learning models can integrate genomic, clinical, and environmental data to support precision prevention strategies, personalised care plans, and informed counselling.

Collaborative Research Across Disciplines

Progress in genomic medicine for Down syndrome requires close collaboration between paediatricians, geneticists, molecular biologists, bioinformaticians, and social scientists. Interdisciplinary teams facilitate translation of genomic discoveries into clinical practice, ensure ethical and culturally sensitive implementation, and foster innovation in preventive strategies and therapeutic development.

This forward-looking perspective emphasises that ongoing research, technological innovation, and collaborative efforts are key to advancing the prevention, early detection, and personalised management of Down syndrome in paediatric care.